IP Library Granted Patent US 7,259,268
Granted Patent B2
US 7,259,268 · App. 11/028,487 · Granted Aug 21, 2007

Method for purification of paclitaxel from paclitaxel-containing materials

Assignee: Samyang Genex Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,259,268
App. No.
11/028,487
Granted
Aug 21, 2007
Kind
B2
Abstract

This invention relates to methods for purification of paclitaxel from a paclitaxel-containing material. The method comprises the following steps: (a) extracting a paclitaxel-containing material with an organic solvent to obtain an extract, and concentrating the extract; (b) adding the concentrate with an organic solvent which is not mixed with water to separate an organic solvent phase and then concentrating; (c) subjecting the concentrate to normal phase chromatography to obtain an eluate; (d) dissolving the eluate in an acetone or dichloromethane followed by adding pentane or hexane to form a precipitate; and (e) subjecting the precipitate to high performance liquid chromatography. According to the method of the present invention, paclitaxel of over 99.5% purity can be easily obtained from a Taxus genus plant with a high yield.

Claims (26)

1. A method of purifying paclitaxel, consisting essentially of:

(a) extracting a plant belonging to a Taxus genus, a cell, or a cell culture thereof, with an organic solvent to obtain an extract, and concentrating the extract;

(b) adding an organic solvent which is not mixed with water to the concentrate to separate an organic solvent phase and then concentrating;

(c) subjecting the concentrate to normal phase chromatography to obtain an eluate;

(d) dissolving the eluate in an acetone or dichloromethane followed by adding pentane or hexane to form a precipitate, wherein about 5 to 100 mg of the eluate is dissolved in 1 ml of acetone or dichloromethane, and pentane or hexane is added in an amount such that the precipitate upon subjecting to high performance liquid chromatography yields paclitaxel of at least 99.5% purity;

(e) subjecting the precipitate to high performance liquid chromatography; and

(f) recovering paclitaxel of at least said purity, wherein the volume ratio of acetone or dichloromethane to pentane or hexane is in a range of 1:3 to 1:20.

2. The method of claim 1 , wherein the organic solvent of the step (a) is at least one selected from the group consisting of methanol, ethanol, propanol, and dichloromethane.

3. The method of claim 1 , wherein the organic solvent of the step (b) is selected from the group consisting of an alkylhalide, ether, alcohols of C 4 –C 6 , ethyl acetate, and methyl ethyl ketone.

4. The method of claim 3 , wherein the organic solvent of the step (b) is selected from the group consisting of dichloromethane, carbon tetrachloride, chloroform, 1,2-dichloroethane, di-ethyl ether, methyl-t-butyl ether, di-iso-propyl ether, n-butanol, and n-pentanol.

5. The method of claim 1 , wherein the concentrate of the step (c) is dissolved in at least one solvent selected from the group consisting of dichloromethane, methanol, benzene, acetone, hexane, and ethyl acetate.

6. The method of claim 1 , wherein the elution of the step (c) is subjected with a mixture of methanol and dichloromethane of 0.5˜10%:99.5˜90% (v/v).

7. The method of claim 1 , wherein equilibrium solvent of the step (c) comprises 0.1˜5% (v/v) of methanol and 99.9˜95% (v/v) of dichloromethane, and the elution solvent comprises 0.5˜100% (v/v) of methanol and the rest of dichloromethane.

8. A method of purifying paclitaxel, consisting essentially of the steps of:

(a) extracting a plant belonging to a Taxus genus, a cell, or a cell culture thereof, with an organic solvent to obtain an extract, and concentrating the extract;

(b) adding an organic solvent which is not mixed with water to the concentrate to separate an organic solvent phase and then concentrating;

(c) subjecting the concentrate to normal phase chromatography to obtain an eluate;

(d) dissolving the eluate in methanol followed by adding water to form a precipitate, wherein about 5 to 100 mg of the eluate is dissolved in 1 ml of methanol, and water is added in an amount such that the precipitate upon subjecting to high performance liquid chromatography yields paclitaxel of at least 99.5% purity;

(e) subjecting the precipitate to high performance liquid chromatography; and

(f) recovering paclitaxel of at least said purity, wherein the volume ratio of methanol to water is in a range of 1:3 to 1:20.

9. The method of claim 8 , wherein the organic solvent of the step (a) is at least one selected from the group consisting of methanol, ethanol, propanol, and dichloromethane.

10. The method of claim 8 , wherein the organic solvent of the step (b) is selected from the group consisting of an alkylhalide, ether, alcohols of C 4 –C 6 , ethyl acetate, and methyl ethyl ketone.

11. The method of claim 10 , wherein the organic solvent of the step (b) is selected from the group consisting of dichloromethane, carbon tetrachloride, chloroform, 1,2-dichloroethane, di-ethyl ether, methyl-t-butyl ether, di-iso-propyl ether, n-butanol, and n-pentanol.

12. The method of claim 8 , wherein the concentrate of the step (c) is dissolved in at least one solvent selected from the group consisting of dichloromethane, methanol, benzene, acetone, hexane, and ethyl acetate.

13. The method of claim 8 , wherein the elution of the step (c) is subjected with a mixture of methanol and dichloromethane of 0.5˜10%:99.5˜90% (v/v).

14. The method of claim 8 , wherein equilibrium solvent of the step (c) comprises 0.1˜5% (v/v) of methanol and 99.9˜95% (v/v) of dichloromethane, and the elution solvent comprises 0.5˜100% (v/v) of methanol and the rest of dichloromethane.

Assignments (4)
CHANGE OF ADDRESS Recorded Nov 3, 2021
From: SAMYANG BIOPHARMACEUTICALS CORPORATION
To: SAMYANG BIOPHARMACEUTICALS CORPORATION
Reel/Frame 058013/0696 →
MERGER Recorded Nov 3, 2021
From: SAMYANG BIOPHARMACEUTICALS CORPORATION
To: SAMYANG HOLDINGS CORPORATION
Reel/Frame 058013/0766 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2014
From: SAMYANG GENEX CORPORATION
To: SAMYANG BIOPHARMACEUTICALS CORPORATION
Reel/Frame 032666/0518 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2005
From: PYO, SANG-HYUN; KIM, MOON-SUK; CHO, JIN-SUK; CHOI, HO-JOON; SONG, BONG-KYU
To: SAMYANG GENEX CORPORATION
Reel/Frame 016393/0126 →
Priority Claims (2)
KR 10-2003-0101464 · Dec 31, 2003 · national
KR 10-2004-0106884 · Dec 16, 2004 · national
Continuity (1)
Related Publication 20050154218A1 · Jul 14, 2005